Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
Antibiotics (Basel, Switzerland)|December 16, 2020
Genomic Analysis of CTX-M-Group-1-Producing Extraintestinal Pathogenic E. coli (ExPEc) from Patients with Urinary Tract Infections (UTI) from ColombiaElsa De La Cadena, María Fernanda Mojica, Nathaly Castillo, et al.Journal of Global Antimicrobial Resistance|December 24, 2017
Molecular characterisation of carbapenem-resistant Enterobacter cloacae complex in Colombia: blaKPC and the 'changing landscape'Elsa De La Cadena, Adriana Correa, Juan Sebastián Muñoz, et al.Jac-Antimicrobial Resistance|March 2, 2026
Enterobacter hormaechei co-harbouring bla KPC-2, bla VIM-24, and bla NDM-1: the rise of the 'unholy trinity'Laura J Rojas, Elsa De La Cadena, Steven H Marshall, et al.Antibiotics (Basel, Switzerland)|April 3, 2021
Molecular Analysis of Polymyxin Resistance among Carbapenemase-Producing Klebsiella pneumoniae in ColombiaElsa De La Cadena, María Fernanda Mojica, Juan Carlos García-Betancur, et al.Case Reports in Infectious Diseases|October 1, 2019
Corrigendum to "In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways"Erik Skoglund, Henrietta Abodakpi, Rafael Rios, et al.Case Reports in Infectious Diseases|January 25, 2019
In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated PathwaysErik Skoglund, Henrietta Abodakpi, Rafael Rios, et al.Antibiotics (Basel, Switzerland)|February 9, 2020
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American CountriesTobias Manuel Appel, María Fernanda Mojica, Elsa De La Cadena, et al.Antimicrobial Agents and Chemotherapy|February 2, 2011
Novel VIM metallo-beta-lactamase variant, VIM-24, from a Klebsiella pneumoniae isolate from ColombiaMaria Camila Montealegre, Adriana Correa, David F Briceño, et al.Antibiotics (Basel, Switzerland)|August 26, 2022
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American CountriesJuan Carlos García-Betancur, Elsa De La Cadena, María F Mojica, et al.BMC Infectious Diseases|May 3, 2022
Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutionsChristian Pallares, Cristhian Hernández-Gómez, Tobías Manuel Appel, et al.Pageof 3